Ensign Peak Advisors
SKYE icon

Ensign Peak Advisors’s Skye Bioscience SKYE Stock Holding History

Ensign Peak Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-95,911
Closed -$3.02M – 1736
2025
Q3 		$3.02M Hold
95,911
– – ﹤0.01% 706
2025
Q2 		$3.21M Hold
95,911
– – 0.01% 745
2025
Q1 		$1.22M Hold
95,911
– – ﹤0.01% 1136
2024
Q4 		$2.17M Sell
95,911
-16,589
-15% -$555K ﹤0.01% 902
2024
Q3 		$3.52M Buy
+112,500
New +$5.05M 0.01% 746

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Ensign Peak Advisors's SKYE Position: Q4 2025 in Review

Ensign Peak Advisors sold out of Skye Bioscience (SKYE) in Q4 2025, closing a stake of 95,911 shares — an estimated $3.02M sold.

Ensign Peak Advisors first reported a position in SKYE in Q3 2024 and held it in 5 quarters. The position peaked at $3.52M in Q3 2024. 42 funds tracked by Wall St. Rank hold SKYE as of Q4 2025.

  • Ensign Peak Advisors reported no remaining Skye Bioscience position as of Q4 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 95,911 Skye Bioscience shares in Q4 2025, an estimated $3.02M.
  • Ensign Peak Advisors first reported a position in Skye Bioscience in Q3 2024 and held it in 5 quarters.
  • Ensign Peak Advisors's Skye Bioscience position peaked at $3.52M in Q3 2024.
  • 42 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2025.

Based on Ensign Peak Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.